Metraipolis › archive › dc_328b014c890a

Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence… — Europe PMC PMID:41156265

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41156265
DOI
10.3390/jcm14207395
License (as archived)
solo-consultazione
Archived
2026-11-09T04:49:16.653Z
SHA-256 of the archived text
28b24833c4728911b6693638b5b55370e7f5316a3ac094562f0c64412a68b10c
Stable URL of this page
https://metraipolis.com/documento/dc_328b014c890a

How to cite

Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence… — Europe PMC PMID:41156265 — Europe PMC (en), https://europepmc.org/article/MED/41156265 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_328b014c890a (Metraipolis archive dc_328b014c890a, sha256 28b24833c4728911b6693638b5b55370e7f5316a3ac094562f0c64412a68b10c)
BibTeX
@misc{dc328b014c890a,
  title = {Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence… — Europe PMC PMID:41156265},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41156265},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_328b014c890a; sha256 28b24833c4728911b6693638b5b55370e7f5316a3ac094562f0c64412a68b10c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41156265. Agents can read the archived copy with the MCP tool read_document.